We sought to explore demographic and clinical risk factors for irAEs in patients receiving anti-PD1 or anti-PDL1 in a large multiethnic cohort of patients with lung cancer treated with ICIs, allowing for particularly robust comparisons of ICIs alone versus concurrent chemotherapy, as well as racial subgroups. This evidence concerns the gene PDCD1 and lung cancer.